Hepion Pharmaceuticals, Inc.
HEPA
Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Morristown, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver d…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$7M
▲ +37.3% YoY
Op. Margin
–
ROIC
-202.02%
▲ +177.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▲ +82.0% YoY
Op. Cash Flow (TTM)
-$2M
▲ +82.0% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with HEPA
Hepion Pharmaceuticals (HEPA) in three numbers
Questions about Hepion Pharmaceuticals
Is Hepion Pharmaceuticals (HEPA) overvalued?
Hepion Pharmaceuticals trades at 0.09 times earnings. Intrinsiqq's fair value calculator has no opening value for HEPA, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Hepion Pharmaceuticals a high-quality business?
Hepion Pharmaceuticals scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$4M, and its weakest is return on capital at -202.0%. The Quality tab shows every check against its target.
Does Hepion Pharmaceuticals (HEPA) pay a dividend?
No. Hepion Pharmaceuticals (HEPA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 8 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in HEPA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HEPA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.